Ceccarelli M, Barthel FP, Malta TM, et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016;164(3):550-63. doi:10.1016/j.cell.2015.12.028
Bandopadhayay P, Ramkissoon LA, Jain P, et al. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet. 2016;48(3):273-82. doi:10.1038/ng.3500
Hata AN, Niederst MJ, Archibald HL, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22(3):262-9. doi:10.1038/nm.4040
Petrovics G, Li H, Stümpel T, et al. A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. EBioMedicine. 2015;2(12):1957-64. doi:10.1016/j.ebiom.2015.10.028
Keum JW, Shin A, Gillis T, et al. The HTT CAG-Expansion Mutation Determines Age at Death but Not Disease Duration in Huntington Disease. Am J Hum Genet. 2016;98(2):287-98. doi:10.1016/j.ajhg.2015.12.018
Liu LY, Alexa K, Cortes M, et al. Cannabinoid receptor signaling regulates liver development and metabolism. Development. 2016;143(4):609-22. doi:10.1242/dev.121731
Deribe YL, Shi Y, Rai K, et al. Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma. Proc Natl Acad Sci U S A. 2016;113(9):E1296-305. doi:10.1073/pnas.1513801113
Gannon HS, Kaplan N, Tsherniak A, et al. Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. Mol Cancer Res. 2016;14(2):207-15. doi:10.1158/1541-7786.MCR-15-0321
Mullane SA, Van Allen EM. Precision medicine for advanced prostate cancer. Curr Opin Urol. 2016;26(3):231-9. doi:10.1097/MOU.0000000000000278
McGranahan N, Furness AJS, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463-9. doi:10.1126/science.aaf1490